Naofumi Hara 研究室

主宰者：Naofumi Hara

岡山大学・Okayama University Hospital

AI 要約（直近 5 年の研究成果）

本研究室では、遺伝子変異を持つ肺がんに対する薬物療法の効果と耐性機構の解明に取り組んでいます。特にEGFR遺伝子やALK遺伝子の変異を持つ非小細胞肺がんを対象として、従来の分子標的薬の有効性を向上させ、薬剤耐性の克服方法を探索することが研究の中心課題です。患者由来の細胞株を用いた培養実験、遺伝子改変マウスを用いた移植腫瘍モデル、臨床症例の分析などを組み合わせたアプローチにより、治療抵抗性の原因となる分子機構を同定しています。具体的には、標準治療薬であるオシメルチニブやアレクチニブに対する耐性が生じるメカニズム、例えば新たな遺伝子変異の出現や細胞周期制御機構の関与を明らかにしています。さらに、単一の薬物では効果不十分な症例に対して、複数の治療法を組み合わせることで抗腫瘍効果を増強する戦略を検討しており、免疫細胞の活性化を促進する併用療法や血管新生阻害剤との組み合わせなどの新しい治療アプローチを提案しています。これらの基礎研究から得られた知見は、臨床現場での個別化医療の実現につながることが期待されています。

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

外部リンク

研究成果（30 件）

[2026] Afatinib Overcomes Osimertinib Resistance via Egfr <scp>V804F</scp> Mutation in a Syngeneic Egfr ‐Mutant Lung Cancer Mouse Model
DOI: https://doi.org/10.1111/cas.70431
[2026] <scp>TGF</scp> ‐β Inhibitor Potentiates Osimertinib‐Induced Anti‐Tumor Immunity in Egfr ‐Mutant Lung Cancer
DOI: https://doi.org/10.1111/cas.70352
[2026] Adenocarcinoma of the Lung With Metastasis to the Small Intestine: Case Report
DOI: https://doi.org/10.1002/rcr2.70511
[2025] Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in ALK-rearranged non-small-cell lung cancer cell lines
DOI: https://doi.org/10.1016/j.lungcan.2025.108415
[2025] Data from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.c.8125941
[2025] Supplementary Figure S1 from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.30516024
[2025] Supplementary Figure S2 from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.30516021
[2025] Endotracheal and Endobronchial Metastases in Epidermal Growth Factor Receptor Exon 19 Deletion Lung Adenocarcinoma: A Case Successfully Managed with Bronchoscopic Therapy and Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
DOI: https://doi.org/10.2169/internalmedicine.6220-25
[2025] Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.mct-25-0002
[2025] 女中奉公の物語 : 一七～一九世紀ユーラシアにおけるドメスティックかつグローバルな歴史の語り

続きを表示（残り 20 件）

[2025] A Prompt Diagnosis of Ascites and Dramatic Effect of Alectinib for Advanced Lung Adenocarcinoma Harboring EML4-ALK Fusion
DOI: https://doi.org/10.2169/internalmedicine.5397-25
[2025] Supplementary Figure S4 from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.30516015
[2025] Supplementary Figure S3 from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.30516018
[2024] A randomized, open-label phase II study on the preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: The OLCSG2101 study protocol
DOI: https://doi.org/10.1016/j.resinv.2024.07.017
[2024] Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non‐small‐cell lung cancer
DOI: https://doi.org/10.1002/ijc.34842
[2023] CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
DOI: https://doi.org/10.21037/tlcr-23-99
[2023] Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK‐rearranged non‐small cell lung cancer
DOI: https://doi.org/10.1111/cas.15958
[2023] Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer
DOI: https://doi.org/10.1016/j.resinv.2023.06.005
[2023] 早稲田大学図書館所蔵「揚屋議定書」
[2023] Synthesis and reactivity of Al–Ni bimetallic complexes
DOI: https://doi.org/10.1016/j.poly.2023.116823
[2022] X-Type Aluminyl Ligands for Transition-Metal Catalysis
DOI: https://doi.org/10.1021/acscatal.1c04340
[2021] Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors
DOI: https://doi.org/10.1007/s00432-021-03615-5
[2021] VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers
DOI: https://doi.org/10.1111/cas.14801
[2021] Rh Complex with Unique Rh–Al Direct Bond: Theoretical Insight into its Characteristic Features and Application to Catalytic Reaction via σ-Bond Activation
DOI: https://doi.org/10.1007/s11244-021-01491-4
[2021] C2-selective alkylation of pyridines by rhodium–aluminum complexes
DOI: https://doi.org/10.1016/j.tet.2021.132339
[2021] C2-Selective silylation of pyridines by a rhodium–aluminum complex
DOI: https://doi.org/10.1039/d1cc00278c
[2021] The clinical value of penicillin G outweighs its usage restriction due to a too-much concern for hyperkalemia
DOI: https://doi.org/10.1080/1120009x.2021.1994689
[2021] Synthesis, Electronic Properties, and Lewis Acidity of Rhodium Complexes Bearing X-Type PBP, PAlP, and PGaP Pincer Ligands
DOI: https://doi.org/10.1246/bcsj.20210068
[2021] Selective C–O Bond Reduction and Borylation of Aryl Ethers Catalyzed by a Rhodium–Aluminum Heterobimetallic Complex
DOI: https://doi.org/10.1021/jacs.1c03038
[2021] The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression
DOI: https://doi.org/10.1016/j.ejca.2021.02.040

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。

AI 要約（直近 5 年の研究成果）

外部リンク

関連研究室(8 件)

研究成果（30 件）

科研費（0 件）

所属学会・役職（0 件）